Natera, Inc. (NTRA) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 27 analysts12.3% Below Target
NTRA trades 12.3% below Wall Street's consensus target of $259.88.
Current Price$231.41
Average Target$259.88
Target
Current
Low$220.00
Median$267.50
High$285.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-0.5%
(Declining)
Analyst Spread25.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes NTRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 27 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
NTRA Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Natera, Inc. (NTRA) has a Wall Street consensus price target of $259.88, based on estimates from 27 covering analysts. With the stock currently trading at $231.41, this represents a potential upside of +12.3%. The company has a market capitalization of $33.14B.
Analyst price targets range from a low of $220.00 to a high of $285.00, representing a 25% spread in expectations. The median target of $267.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 24 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NTRA trades at a trailing P/E of -152.2x. Analysts expect EPS to grow -0.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+59.7%
Industry Consensus
Avg Forward P/E
106.1x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
 CGENCompugen Ltd. | $190M | $2.01 | $4.50 | +123.9% | Buy | — | 14 |
 MYRGMYR Group Inc. | $7.2B | $461.10 | $412.67 | -10.5% | Hold | 40.3x | 21 |
 PACBPacific Biosciences of California, Inc. | $435M | $1.40 | $1.00 | -28.6% | Buy | — | 18 |
 PRMEPrime Medicine, Inc. | $583M | $3.23 | $17.25 | +434.1% | Buy | — | 9 |
 CDNACareDx, Inc | $1.4B | $26.18 | $27.00 | +3.1% | Buy | 28.0x | 13 |
 TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
 DHRDanaher Corporation | $125.4B | $177.17 | $230.89 | +30.3% | Buy | 21.0x | 43 |
 AAgilent Technologies, Inc. | $35.9B | $127.06 | $154.75 | +21.8% | Buy | 21.0x | 41 |
NTRA — Frequently Asked Questions
Quick answers to the most common questions about buying NTRA stock.
What is the NTRA stock price target for 2026?
Natera, Inc. (NTRA) has a consensus 12-month price target of $259.88, implying 12.3% upside from $231.41. The 27 analysts covering NTRA see moderate appreciation potential.
Is NTRA a buy, sell, or hold?
NTRA has a consensus rating of "Buy" based on 27 Wall Street analysts. The rating breakdown is predominantly bullish, with 24 Buy/Strong Buy ratings. The consensus 12-month price target of $259.88 implies 12.3% upside from current levels.
Is NTRA stock overvalued or undervalued?
NTRA's current price is $231.41 with a consensus target of $259.88 (12.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can NTRA stock go?
The most bullish Wall Street analyst has a price target of $285 for NTRA, while the most conservative target is $220. The consensus of $259.88 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover NTRA stock?
NTRA is heavily covered by Wall Street, with 27 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 24 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NTRA stock forecast?
The 12-month NTRA stock forecast based on 27 Wall Street analysts shows a consensus price target of $259.88, with estimates ranging from $220 (bear case) to $285 (bull case). The median consensus rating is "Buy".
Should I buy NTRA stock?
Wall Street analysts are optimistic on NTRA, with a "Buy" consensus rating and $259.88 price target (12.3% upside). 24 of 27 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NTRA price targets vary so much?
NTRA analyst price targets range from $220 to $285, a 25% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $259.88 consensus represents the middle ground.
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into NTRA consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare